Monte Rosa Therapeutics, Inc. Federal State And Local Income Tax Expense Benefit Continuing Operations
Monte Rosa Therapeutics, Inc. (GLUE) reported Federal State And Local Income Tax Expense Benefit Continuing Operations of -$1.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Expense Statement › Income Tax
us-gaap:FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations · last filed 2026-03-17
- Monte Rosa Therapeutics, Inc. federal state and local income tax expense benefit continuing operations for fiscal 2025 was -$1.10M, a 142.68% decline from fiscal 2024.
- Monte Rosa Therapeutics, Inc. federal state and local income tax expense benefit continuing operations for fiscal 2024 was $2.57M.
| Period end | Federal State And Local Income Tax Expense Benefit Continuing Operations 12 month |
|---|---|
| 2025-12-31 | -$1.10M 10-K · filed 2026-03-17 |
| 2024-12-31 | $2.57M 10-K · filed 2026-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |